Suppression by resveratrol of prostaglandin D2-stimulated osteoprotegerin synthesis in osteoblasts

Prostaglandins Leukotrienes and Essential Fatty Acids

Volumn 91, Issue 3, 2014, Pages 73-80

  Kuroyanagi, Gen ^a,b   Mizutani, Jun ^a   Kondo, Akira ^a,b   Yamamoto, Naohiro ^a,b   Matsushima Nishiwaki, Rie ^b   Otsuka, Takanobu ^a   Kozawa, Osamu ^b   Tokuda, Haruhiko ^b,c  

^a NAGOYA CITY UNIVERSITY GRADUATE SCHOOL OF MEDICAL SCIENCES   (Japan)

^b GIFU UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^c NATIONAL CENTER FOR GERIATRICS AND GERONTOLOGY   (Japan)

Author keywords

Osteoblast; Osteoprotegerin; Resveratrol

Indexed keywords

2 (2 AMINO 3 METHOXYPHENYL)CHROMONE; 4 (4 FLUOROPHENYL) 2 (4 METHYLSULFINYLPHENYL) 5 (4 PYRIDYL)IMIDAZOLE; ANTHRA[1,9 CD]PYRAZOL 6(2H) ONE; ENZYME ACTIVATOR; MITOGEN ACTIVATED PROTEIN KINASE P38; MYOSIN LIGHT CHAIN PHOSPHATASE; OSTEOPROTEGERIN; PROSTAGLANDIN D2; RESVERATROL; SRT 1720; STRESS ACTIVATED PROTEIN KINASE; UNCLASSIFIED DRUG; ENZYME INHIBITOR; MESSENGER RNA; MITOGEN ACTIVATED PROTEIN KINASE; SIRT1 PROTEIN, MOUSE; SIRTUIN 1; STILBENE DERIVATIVE; TNFRSF11B PROTEIN, MOUSE;

ANIMAL CELL; ARTICLE; BONE METABOLISM; CONTROLLED STUDY; ENZYME PHOSPHORYLATION; FATTY ACID ANALYSIS; GENE EXPRESSION; METABOLIC REGULATION; MOUSE; NEWBORN; NONHUMAN; OSTEOBLAST; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN LIPID INTERACTION; PROTEIN SECRETION; PROTEIN SYNTHESIS INHIBITION; SIGNAL TRANSDUCTION; ANIMAL; BIOSYNTHESIS; CELL LINE; CYTOLOGY; DRUG EFFECTS; HUMAN; METABOLISM;

VITACEAE;

ANIMALS; CELL LINE; ENZYME INHIBITORS; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; HUMANS; MAP KINASE SIGNALING SYSTEM; MICE; OSTEOBLASTS; OSTEOPROTEGERIN; PROSTAGLANDIN D2; RNA, MESSENGER; SIRTUIN 1; STILBENES;

EID: 84905573471     PISSN: 09523278     EISSN: 15322823     Source Type: Journal    
DOI: 10.1016/j.plefa.2014.04.003     Document Type: Article

References (32)

1. Karsenty G., Wagner E.F. Reaching a genetic and molecular understanding of skeletal development. Dev. Cell 2002, 2:389-406.
2. Parfit A.M. Targeted and nontargeted bone remodeling: relationship to basic multice. Bone 2002, 30:5-7.
3. Ross P.A. Osteoclast biology and bone resorption. Primer on the Metabolic Bone Diseases of Minerel Metabolism 2013, John Wiley & Sons, Inc., Hoboken, NJ. 8th ed. C.J. Rosen (Ed.).
4. Simonet W.S., Lacey D.L., Dunstan C.R., Kelley M., Chang M.S., Lüthy R., Nguyen H.Q., Wooden S., Bennett L., Boone T., Shimamoto G., DeRose M., Elliott R., Colombero A., Tan H.L., Trail G., Sullivan J., Davy E., Bucay N., Renshaw-Gegg L., Hughes T.M., Hill D., Pattison W., Campbell P., Sander S., Van G., Tarpley J., Derby P., Lee R., Boyle W.J. Osteoprotegerin: a novel secreted protein involved in the regulation of bone density. Cell 1997, 89:309-319.
5. Mizuno A., Kanno T., Hoshi M., Shibata O., Yano K., Fujise N., Kinosaki M., Yamaguchi K., Tsuda E., Murakami A., Yasuda H., Higashio K. Transgenic mice overexpressing soluble osteoclast differentiation factor (sODF) exhibit severe osteoporosis. J. Bone Miner. Metab. 2002, 20:337-344.
6. Hikiji H., Takato T., Shimizu T., Ishii S. The roles of prostanoids, leukotrienes, and platelet-activating factor in bone metabolism and disease. Prog. Lipid Res. 2008, 47:107-126.
7. 2 metabolite stimulates collagen synthesis by human osteoblasts during calcification. Prostaglandins 1991, 41:303-313.
8. 2 by human osteoblasts and modulation of osteoprotegerin, RANKL, and cellular migration by DP and CRTH2 receptors. J. Bone Miner. Res. 2005, 20:672-681.
9. 2 induces interleukin-6 synthesis via Ca2+ mobilization in osteoblasts: regulation by protein kinase C. Prostaglandins Leukot. Essent. Fat. Acids 1999, 61:189-194.
10. 2-induced interleukin-6 synthesis in osteoblasts. Prostaglandins Leukot. Essent. Fat. Acids 2008, 79:41-46.
11. 2-stimulated heat shock protein 27 induction in osteoblasts. Cell. Signal. 2001, 13:535-541.
12. 2-stimulated heat shock protein 27 induction in osteoblasts. Exp. Ther. Med. 2010, 1:579-583.
13. Jankun J., Selman S.H., Swiercz R., Skrzypczak-Jankun E. Why drinking green tea could prevent cancer. Nature 1997, 387:561.
14. Harbourne J.B., Williams C.A. Advances in flavonoid research since 1992. Phytochemistry 2000, 55:481-504.
15. Baur J.A., Pearson K.J., Price N.L., Jamieson H.A., Lerin C., Kalra A., Prabhu V.V., Allard J.S., Lopez-Lluch G., Lewis K., Pistell P.J., Poosala S., Becker K.G., Boss O., Gwinn D., Wang M., Ramaswamy S., Fishbein K.W., Spencer R.G., Lakatta E.G., Le Couteur D., Shaw R.J., Navas P., Puigserver P., Ingram D.K., de Cabo R., Sinclair D.A. Resveratrol improves health and survival of mice on a high-calorie diet. Nature 2006, 444:37-42.
16. Koo S.H., Montminy M. In vino veritas: a tale of two sirt1s?. Cell 2006, 127:1091-1093.
17. Renaud S., de Lorgeril M. Wine, alcohol, platelets, and the French paradox for coronary heart disease. Lancet 1992, 339:1523-1526.
18. Kubo J.T., Stefanick M.L., Robbins J., Wactawski-Wende J., Cullen M.R., Freiberg M., Desai M. Preference for wine is associated with lower hip fracture incidence in post-menopausal women. BMC Women's Health 2013, 13:36.
19. Sudo H., Kodama H., Amagai Y., Yamamoto S., Kasai S. in vivo differentiation and calcification in a new clonal osteogenic cell line derived from newborn mouse calvaria. J. Cell Biol. 1983, 96:191-198.
20. 2 in osteoblast-like cells. Exp. Cell. Res. 1992, 198:130-134.
21. Laemmli U.K. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature 1970, 227:680-685.
22. Kato K., Ito H., Hasegawa K., Inaguma Y., Kozawa O., Asano T. Modulation of the stress-induced synthesis of hsp27 and αB-crystallin by cyclic AMP in C6 glioma cells. J. Neurochem. 1996, 66:946-950.
23. Milne J.C., Lambert P.D., Schenk S., Carney D.P., Smith J.J., Gagne D.J. Small molecule activators of SIRT1 as therapeutics for the treatment of type 2 diabetes. Nature 2007, 450:712-716.
24. Kyriakis J.M., Avruch J. Mammalian mitogen-activated protein kinase signal transduction pathways activated by stress and inflammation. Physiol. Rev. 2001, 81:807-869.
25. Alessi D.R. PD98059 is a specific inhibitor of the activation of mitogen-activated protein kinase in vitro and in vivo. J. Biol. Chem. 1995, 270:27489-27494.
26. Cuenda A., Rouse J., Doza Y.N., Meier R., Cohen P., Gallagher T.F., Young P.R., Lee J.C. SB203580 is a specific inhibitor of a MAP kinase homologue which is stimulated by cellular stresses and interleukin-1. FEBS Lett. 1995, 364:229-233.
27. Bennett B.L., Sasaki D.T., Murray B.W., O'Leary E.C., Sakata S.T., Xu W., Leisten J.C., Motiwala L., Peierce S., Satoh Y., Bhagwat S.S., Manning A.M., Anderson D.W. SP600125, an anthrapyrazolone inhibitor of Jun N-terminal Kinase. Proc. Natl. Acad. Sci. U.S.A 2001, 98:13681-13686.
28. Fukata Y., Amano M., Kaibuchi K. Rho-Rho-kinase pathway in smooth muscle contraction and cytoskeletal reorganization of non-muscle cells. Trends Pharmacol. Sci. 2001, 22:32-39.
29. Ito M., Nakano T., Erdodi F., Hartshorne D.J. Myosin phosphatase: structure, regulation and function. Mol. Cell. Biochem. 2004, 259:197-209.
30. 2 stimulates calcification of human osteoblastic cells. Biochem. Biophys. Res. Commun. 1989, 159:1206-1212.
31. Walle T., Hsieh F., DeLegge M.H., Oatis J.E., Walle U.K. High absorption but very low bioavailability of oral resveratrol in humans. Drug Metab. Dispos. 2004, 32:1377-1382.
32. 2, are correlated with increasing propensity towards sleep in rats. Brain Res. 1997, 751:81-89.